Porton Fine Chemicals Ltd (SHE:300363) — Market Cap & Net Worth
Market Cap & Net Worth: Porton Fine Chemicals Ltd (300363)
Porton Fine Chemicals Ltd (SHE:300363) has a market capitalization of $1.84 Billion (CN¥12.59 Billion) as of October 14, 2026. Listed on the SHE stock exchange, this China-based company holds position #6387 globally and #1250 in its home market, demonstrating a -3.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Porton Fine Chemicals Ltd's stock price CN¥23.17 by its total outstanding shares 543442176 (543.44 Million).
Porton Fine Chemicals Ltd Market Cap History: 2015 to 2026
Porton Fine Chemicals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.98 Billion to $1.84 Billion (0.34% CAGR). Check 300363 stock price and chart for real-time trading data and today's change.
Porton Fine Chemicals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Porton Fine Chemicals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Porton Fine Chemicals Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.42x
Porton Fine Chemicals Ltd's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.98 Billion | $1.02 Billion | $110.39 Million | 1.94x | 17.90x |
| 2016 | $1.46 Billion | $1.33 Billion | $171.19 Million | 1.10x | 8.55x |
| 2017 | $971.73 Million | $1.18 Billion | $107.45 Million | 0.82x | 9.04x |
| 2018 | $649.99 Million | $1.18 Billion | $124.49 Million | 0.55x | 5.22x |
| 2019 | $1.06 Billion | $1.55 Billion | $185.55 Million | 0.68x | 5.69x |
| 2020 | $2.71 Billion | $2.07 Billion | $324.42 Million | 1.31x | 8.34x |
| 2021 | $6.64 Billion | $3.11 Billion | $523.92 Million | 2.14x | 12.68x |
| 2022 | $3.04 Billion | $7.03 Billion | $2.01 Billion | 0.43x | 1.52x |
| 2023 | $1.94 Billion | $3.67 Billion | $266.86 Million | 0.53x | 7.25x |
| 2024 | $1.25 Billion | $3.01 Billion | -$287.75 Million | 0.42x | N/A |
Competitor Companies of 300363 by Market Capitalization
Companies near Porton Fine Chemicals Ltd in the global market cap rankings as of October 14, 2026. See Porton Fine Chemicals Ltd (300363) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Porton Fine Chemicals Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #528 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #580 globally with a market cap of $46.89 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #643 globally with a market cap of $42.48 Billion USD ( CN¥290.31 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #528 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #580 | GALDERMA GROUP AG | NYSE:GALDY | $46.89 Billion | $40.22 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #643 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.48 Billion | CN¥45.51 |
Porton Fine Chemicals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Porton Fine Chemicals Ltd's market cap moved from $1.98 Billion to $ 1.84 Billion, with a yearly change of 0.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.84 Billion | -0.30% |
| 2025 | CN¥1.85 Billion | +47.37% |
| 2024 | CN¥1.25 Billion | -35.22% |
| 2023 | CN¥1.94 Billion | -36.34% |
| 2022 | CN¥3.04 Billion | -54.21% |
| 2021 | CN¥6.64 Billion | +145.50% |
| 2020 | CN¥2.71 Billion | +156.18% |
| 2019 | CN¥1.06 Billion | +62.47% |
| 2018 | CN¥649.99 Million | -33.11% |
| 2017 | CN¥971.73 Million | -33.60% |
| 2016 | CN¥1.46 Billion | -25.95% |
| 2015 | CN¥1.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 14th, 2026 the market cap of Porton Fine Chemicals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.84 Billion USD |
| MoneyControl | $1.84 Billion USD |
| MarketWatch | $1.84 Billion USD |
| marketcap.company | $1.84 Billion USD |
| Reuters | $1.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Porton Fine Chemicals Ltd
Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more